Meperidine

HE UNIQUE TOXIC AND ADverse effects of meperidine hydrochloride1 have prompted a number of expert panels convened by national health care policy organizations to declare meperidine an inappropriate medication in the elderly population.2-5 Among the opioids, meperidine has uniquely been shown to be less likely to achieve pain control and more likely to produce delirium Table 1 ; . Additionally, its major metabolite, normeperidine, is associated in a dosedependent manner with twitches, myoclonus, and seizures.13, 20 Normeperidine is renally excreted and accumulates in those with renal insufficiency, including many older adults who have a normal serum creatinine level. In contrast to other opioid adverse effects, the neurologic excitation from normeperidine is not reversible and may be enhanced with naloxone hydrochloride.21 For more than a decade now, the Beers criteria, a consensus-based list of drugs to avoid in the elderly, has designated me. 11 inhibited as required with supplemental injections of meperidine to the maximal cumulative dose of 2.5 mg kg. During their subsequent body-insulated trials, meperidine was administered according to the same dosing schedule as used in their body-exposed trial s ; . In order to achieve a balanced design, the first trial for the other three subjects was a body-insulated condition. For these subjects, the meperidine dosing schedule followed the average schedule determined from the two body-exposed trials of the first three subjects tested. In their remaining body-exposed trials, meperidine was given according to the predetermined schedule unless shivering occurred; in these cases the next doses were given as required to suppress shivering, to the maximum cumulative dose. In all trials, arterial oxygen saturation was monitored to screen for respiratory depression. Pulse amplitude on the oximeter was monitored to confirm that saturation values were reliable; if pulse amplitude was inadequate, alternate fingers were used. If saturation decreased below ~95%, subjects were roused and encouraged to breathe more vigorously. The subjects remained immersed until one of four removal criteria was met: 1 ; immersion time of 45 minutes; 2 ; voluntary request by a subject for removal; 3 ; Tes reached 34 C; or 4 ; termination of immersion by investigator for safety reasons. Upon removal from the cold water, subjects were placed in a 40 stirred water bath until Tes was 36 C and they felt comfortably warm. Presently, all drugs specifically indicated for the treatment of HIV and its opportunistic infections are on Formulary. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE AGENTS All oral FDA-approved antineoplastic and immunosuppressive agents are eligible for coverage under the prescription drug benefit. AUTONOMIC & CENTRAL NERVOUS SYSTEM ALZHEIMER'S AGENTS Donepezil Aricept Memantine Namenda Rivastigmine Exelon ANALGESICS, NARCOTIC APAP Caffeine Butalbital generics only APAP or ASA Codeine generics only APAP Hydrocodone generics only ASA Caffeine Butalbital generics only Buprenorphine Suboxone, Subutex Codeine APAP or ASA generics only Caffeine Butalbital Fentanyl Transdermal QL generics 4 bxs of 5 patches 30 days ; Fentanyl Transmucosal Actiq Hydromorphone generics only Meperidine generics only Methadone generics only Morphine Sulfate generics only Morphine Sulfate SR generic Kadian Oxycodone APAP generics only Oxycodone ASA generics only Oxycodone SA generics only Propoxyphene HCl generics only Propoxyphene APAP 650mg generics only Propoxyphene APAP 325mg generics only ANALGESICS, NONSTEROIDAL ANTIINFLAMMATORY Celecoxib QL, ST Celebrex 60 caps 30 days ; Diclofenac generics only Diclofenac Misoprostol Arthrotec Etodolac generics only Flurbiprofen generics only Ibuprofen 200mg OTC generics only Ibuprofen generics only Indomethacin SR generics only Ketorolac generics only Nabumetone generics only Naproxen Sodium OTC generics only Naproxen EC generics only Naproxen Suspension Naprosyn Oxaprozin generics only.
APPENDIX In addition to the Writing Committee, the following Investigators and Institutions participated in the study, all in Italy in the order of patients contributed to the study ; : Malattie Tromboemboliche ed Emorragiche, Ematologia con Trapianto, Azienda Ospedaliera Universitaria di Palermo S. Siragusa, G. Bonifacio, R. Anastasio, A. Malato, L. Lo Coco, V. Abbadessa Scienze Mediche e Chirurgiche, Clinica Medica II, Universit di Padova P. Prandoni, A. Concolato, M. Perlati, C. Bullo, L. Hartmann, R. Pesavento, A. Pagnan Medicina Interna e Patologia Clinica, Ospedale di Piacenza D. Imberti, E. Croci Azienda Ospedaliera di Cosenza C. Bova, R. Ricchio Scienze Mediche e Chirurgiche, Medicina Interna, Universit di Padova F. Fabris, M. Scapin, M. Giannocaro Medicina Clinica, Universit dell'Insubria W. Ageno, F. Dentali Medicina Interna ed Angiologia, Azienda Ospedaliera Universitaria di Parma R. Quintavalla, C. Pattacini Clinica Medica III, Universit di Pavia C. Balduini, G. Bertolino, E. Venturi Emostasi e Trombosi, Struttura Operativa di Medicina, Azienda Ospedaliera di Pordenone P. Tropeano, L. Virgolini Medicina Generale, Azienda Ospedaliera di Padova B. Girolami, S. Bottegal, G. Brighenti, G. Baggio Azienda Alto Vicentino di Thiene, Vicenza C. Sardella, E. Fongaro, L. Guadagnin Medicina Interna ed Angiologia, Centro Studi Neurolesi, Messina S. Rotondo Oncologia Medica, Ospedale di Taormina F. Vitale Angiologia e Chirurgia Vascolare, Trento A. Bertoldi Medicina Interna Valdichiana, Ospedale di Cortona R. Migliacci Casa di Cura Liotti, Perugia G. Rosi, A. Lu Priore Medicina Generale, Ospedale di Belluno F. Tremolada, L. Cimarosto. PBMC were separated from heparinized whole blood of normal donors by Ficoll-Hypaque density gradient centrifugation as described.13. IM intramuscular; IV intravenous; PO oral; SC subcutaneous. * Meperidine should be used for acute dosing only and not used for chronic pain management meperidine has a short half-life and a toxic metabolite: normeperidine ; . Its use should also be avoided in patients with renal insufficiency, chronic heart failure, hepatic insufficiency, or the elderly because of the potential for toxicity due to accumulation of the metabolite normeperidine. Seizures, confusion, tremors, or mood alterations may be seen. Many equianalgesic tables underestimate methadone potency--more studies are needed. Parenteral: Program utilizes 10 mg for short-term dosing and 2 mg for chronic dosing. Oral: Program utilizes 20 mg for short-term dosing and 3 mg for chronic dosing. Acute dosing opiate naive ; : 60 mg. Chronic dosing: 30 mg. Propoxyphene HCL: 130 mg; Napsylate: 200 mg not recommended for chronic pain management and therefore not listed above ; . Adapted with permission from D. McAuley, GlobalRPh, Inc. globalrph narcoticonv and mephenytoin. For more information, contact: WORLD HEALTH ORGANIZATION Department of HIV AIDS 20, avenue Appia CH-1211 Geneva 27 Switzerland E-mail: hiv-aids who.int : who.int hiv en. In this randomized, controlled trial, every parturient who requested analgesia other than epidural analgesia and agreed to receive systemic analgesia was invited to participate in the study. Approximately 30% of our parturients requested analgesia other than epidural analgesia. Randomization was based on computer-generated codes kept in sequentially numbered opaque envelopes until just before use. After we obtained institutional and Ministry of Health approval for human studies and patients' written informed consent, 88 term parturients with singleton cephalic presentation requesting systemic analgesia ASA physical status I or II ; were recruited. All women were in active labor cervical dilation of 3 6 After randomization, the parturients received either PCIA with remifentanil n 43 ; or infusion of meperidine n 45 ; throughout labor. For blinding, PCIA remifentanil parturients were connected to a dummy IV saline bag, and IV meperidine parturients were connected to a dummy saline PCIA. We chose this and meprobamate.
Rritable bowel syndrome IBS ; , a gastrointestinal GI ; disorder occurring in 10% to 24% of the general population, 1, 2 accounts for 12% of all visits to primary care physicians and 28% of all visits to gastroenterologists.3, 4 The disorder is characterized by chronic abdominal discomfort with altered bowel habits that cannot be explained by structural or biochemical abnormalities.5 IBS can result in significant morbidity, with patients reporting 3 times as many absences from school and work compared to those without the disorder.6 Psychiatric comorbidity is common in patients with IBS; approximately 70% to 90% of individuals who seek treatment for IBS also show symptoms of a psychiatric disorder, 7 including panic disorder, generalized anxiety disorder, social phobia, posttraumatic stress disorder, and major depressive disorder. Conversely, individuals with IBS symptoms who do not seek treatment, an estimated 50% to 86% of the afflicted population, 1 tend not to exhibit psychiatric symptomatology.7 While the etiology of IBS remains unclear, there is considerable evidence of a pathophysiologic linkage between the brain and the enteric nervous system.8 Stress is known to exacerbate bowel symptoms in patients with IBS and healthy subjects, 911 and GI symptoms, such as nausea, abdominal distress, and weight gain loss, frequently are observed in patients with mood and anxiety disorders, suggesting a common etiologic pathway between psychiatric and at least some GI disorders.12 In particular, symptoms of IBS are reported to occur frequently in psychiatric patients. Masand et al.1315 observed IBS in 27% of individuals with major depression, 13 59% of those with dysthymia, 14 and 58% of patients with double depression defined as major depression plus dysthymia ; .15 Similarly, Tollefson et al.16 reported that 37% of patients with generalized anxiety disorder met criteria for IBS, and several studies1719 have reported a correlation between IBS and panic disorder. Additionally, Gupta et al.20 observed IBS in 19% of patients with schizophrenia, and Masand and colleagues21 have reported that IBS occurs frequently among patients seeking treatment for alcohol abuse or dependence. The frequent comorbidity of psychiatric illness and the absence of an identifiable organic cause of IBS raise the possibility that underlying mood or anxiety disorders may.
II. Diagnostic testing A. ECG changes. During the initial few days, diffuse limb leads and precordial leads ; ST segment elevations are common in the absence of reciprocal ST segment depression. PR segment depression is also common and reflects atrial involvement. B. The chest radiograph is often unrevealing, although a small left pleural effusion may be seen. An elevated erythrocyte sedimentation rate and C-reactive protein CRP ; and mild elevations of the white blood cell count are also common. C. Labs: CBC, SMA 12, albumin, viral serologies: Coxsackie A & B, measles, mumps, influenza, ASO titer, hepatitis surface antigen, ANA, rheumatoid factor, anti-myocardial antibody, PPD with candida, mumps. Cardiac enzymes q8h x 4, ESR, blood C&S X 2. D. Pericardiocentesis: Gram stain, C&S, cell count & differential, cytology, glucose, protein, LDH, amylase, triglyceride, AFB, specific gravity, pH. E. Echocardiography is the most sensitive test for detecting pericardial effusion, which may occur with pericarditis. III. Treatment of acute pericarditis nonpurulent ; A. If effusion present on echocardiography, pericardiocentesis should be performed and the catheter should be left in place for drainage. B. Treatment of pain starts with nonsteroidal antiinflammatory drugs, meperidine, or morphine. In some instances, corticosteroids may be required to suppress inflammation and pain. C. Anti-inflammatory treatment with NSAIDs is firstline therapy. 1. Indomethacin Indocin ; 25 mg tid or 75 mg SR qd, OR 2. Ketorolac Toradol ; 15-30 mg IV q6h, OR 3. Ibuprofen Motrin ; 600 mg q8h. D. Morphine sulfate 5-15 mg intramuscularly every 4-6 hours. Meperidine Demerol ; may also be used, 50100 mg IM IV q4-6h prn pain and promethazine Phenergan ; 25-75 mg IV q4h. E. Prednisone, 60 mg daily, to be reduced every few days to 40, 20, 10, and 5 mg daily. F. Purulent pericarditis 1. Nafcillin or oxacillin 2 gm IV q4h AND EITHER 2. Gentamicin or tobramycin 100-120 mg IV 1.5-2 mg kg then 80 mg 1.0-1.5 mg kg ; IV q8h adjust in renal failure ; OR 3. Ceftizoxime Cefizox ; 1-2 gm IV q8h. 4. Vancomycin, 1 gm IV q12h, may be used in place of nafcillin or oxacillin and mercaptopurine. 24-hour duration of effect, depending on the specific drug and individual variation. Hydromorphone. Hydromorphone is significantly more potent than morphine, permitting smaller volumes to be used when injecting equianalgesic doses. Like morphine, it can be administered through oral, parenteral subcutaneous, intramuscular, and intravenous ; , rectal, or intraspinal epidural and intrathecal ; routes. Its relatively short half-life of elimination 2 to 3 hours ; facilitates dose titration but complicates efforts to use hydromorphone for chronic pain. Modified-release formulations, which will increase the convenience of oral therapy for chronic pain, are in development and are currently being reviewed by the US Food and Drug Administration FDA ; . Because hydromorphone is very soluble in water, highconcentration solutions can be made and are particularly suitable for subcutaneous administration, including continuous subcutaneous infusion. A high-potency preparation 10 mg mL ; is commercially available. Side effects associated with hydromorphone are qualitatively similar to those associated with opioids in general, and most often include constipation, nausea, and sedation. Hydromorphone may be preferred over morphine for patients with decreased renal clearance, to preempt the potential for toxicity from morphine metabolite accumulation. Oxycodone. Oxycodone is available in both an immediaterelease and a modified-release 8- to 12-hour duration ; preparation. The immediate-release formulation is available as a single entity and in combination with acetaminophen or aspirin. Lower doses of oxycodone eg, 2.5 mg, 5 mg, 7.5 mg, 10 mg ; in combination with a nonopioid coanalgesic are frequently used for management of acute pain in patients with limited prior opioid exposure. When these drugs are used, care must be taken not to exceed the recommended maximal dose of the coanalgesic for example, 4 g or less of acetaminophen per day ; . The modified-release formulation of oxycodone is now widely used for management of chronic pain. Oxymorphone. Oxymorphone has a short half-life and is both a potent congener of morphine and an active metabolite of oxycodone. It is presently available in suppository and injectable forms. Although an oral form is not yet available, immediaterelease and modified-release formulations are in development and are currently under review by the FDA. Oxymorphone may have particular utility for patients subject to drug-drug interactions since it does not affect the CYP2D6 or CYP3A4 enzymes. Meperidine. Meperidine is not preferred for long-term use because of the risk of toxicity associated with accumulation of. Conclusion: both meperidine and ketoprofen are equally effective in providing postoperative analgesia up to 6 hr, without significant difference in the side effects and none of them provide significant analgesia after 6 hr and meropenem!

Baseline characteristics of the four dose groups were generally well matched Table 1 ; , including several key hemodynamic variables Table 2 ; . However, baseline 6MWDs indicate that the patients who received the 10-mg dose may have represented a somewhat sicker population. Three patients discontinued the study because of adverse events during the 12-week treatment period: two patients because of sudden death 1- and 10-mg-dose groups ; and one patient because of elevated serum aminotransferase concentrations 5-mg-dose group ; . Three patients in the 2.5-mg-dose group also discontinued: one patient because of an inclusion criteria violation pulmonary capillary wedge pressure 15 mm Hg ; , one patient voluntarily withdrew, and one patient was lost to follow-up. All six patients had their last 6MWD carried forward to the 12-week assessment. Two patients 1- and 5-mg-dose groups ; who completed the 12-week treatment period did not have the option to participate in the 12-week open-label extension period. One patient in the 5-mg-dose group voluntarily withdrew from the open-label extension period, and one patient in the 10-mg-dose group voluntarily discontinued from the open-label extension period because of lack of improvement. Exercise capacity. The 6MWD improved for all dose groups combined after 12 weeks of treatment, with a mean increase from baseline of 36.1 m p 0.0001 ; . A similar improvement was observed in all dose groups: 33.9 p 0.0029 ; , 37.1 p 0.0004 ; , 38.1 p 0.0112 ; , and 35.1 p 0.0080 ; m for the 1-, 2.5-, 5-, and 10-mg-dose groups, respectively, and no dose-response relationship was observed Fig. 2A ; . Subgroup analyses Figs. 2B and 2C ; indicate that the 6MWD increased in patients with IPAH 39.9 m, p 0.0001 ; as well as in patients with PAH due to other etiologies 30.2, p 0.0026 ; and for patients in WHO functional class II 37.7 m, p 0.003 ; as well as in those in WHO functional class III 35.2, p 0.001 and mesoridazine. Examples of drugs included in each schedule include: Schedule I: Agents that are not usually acceptable for medical use and have a high potential for abuse and addiction heroin, hallucinogens such as LSD and PCP, and marijuana although some states allow marijuana to be used for medicinal purposes . Schedule II: Agents that have a high potential for abuse but are used for pain management hydromorphone Dilaudid ; , methadone, meperidine Demerol ; , cocaine, oxycodone Percodan ; , and methylphenidate Ritalin . Schedule IIIV: Agents regarded as having less potential for abuse and addiction III: anabolic steroids, codeine and hydrocodone with aspirin or Tylenol, and some barbituates; IV: depressants such as diazepam Valium ; , clonazepam Klonopin ; , and alprazolam Xanax V: antitussives, antidiarrheal, and analgesics that may contain codeine.

Opiate Metabolism Comments Morphine crosses the blood-brain barrier at a low rate, with small quantities of morphine crossing the blood-brain barrier in adults. Morphine-6glucuronide may accumulate after continuous dosing in patients with renal failure, leading to enhanced, prolonged opiate activity. Thus, morphine dose may need to be reduced in patients with significant renal and or hepatic impairment or in the elderly to avoid adverse effects 186 ; . Morphine Two major metabolites: M3G and M6G, which can Morphine Sulfate, MSIR, Oramorph cause adverse effects, if they accumulate. SR, MS Contin, Morphine Sulfate Oral Solution, Roxanol, MSIR Oral Solution, Morphine Sulfate Suppositories, Roxanol-SR, RMS, Kadian, Duramorph, Astramorph, Epimorph, Infumorph, Uniserts, Statex ; Plasma half-life 2-3.5 hrs Duration of action 3-6 hrs Meperidine Demerol, Mepergan ; Plasma half-life 2-4 hrs Duration of action 2-4 hrs Meperidine is metabolized to Normeperidine. Normeperidine has a half-life of 15-30 hours, is renally excreted, and causes seizures, myoclonus, tremors, and central nervous system irritability when it accumulates. Meperidine is a relatively weak opioid with significant anti-cholinergic and local anesthetic properties, with only 10% efficacy of morphine. The oral-to-parental ratio is 4: 1. Meperidine should not be administered in patients with impaired renal function. It should be administered with caution in elderly. Normeperidine is accumulated after long-term meperidine administration, particularly in patients with renal dysfunction, and may cause central nervous system excitatory effects, which may produce naloxone-irreversible multifocal myoclonus and grand-mal seizures. Short-term administration of meperidine may be associated with mild dysphoria. Meperidine is contraindicated in patients on monamine oxidase inhibitors, which may result in severe respiratory depression, hyperpyrexia, central nervous system excitation, delirium and seizures 184 and metamucil. JL. Is there still a place for pethidine in the management of postoperative pain? Curr Anaesth Crit Care 1995; 6: 98-102. Sinatra RS, Lodge K, Sibert K, et al. A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. Anesthesiology 1989; 70: 585-90. Bahar M, Rosen M, Vickers MD. Self-administered nalbuphine, morphine and pethidine. Comparison, by intravenous route, following cholecystectomy. Anaesthesia 1985; 40: 529-32. Vetter TR. Pediatric patient-controlled analgesia with morphine versus meperidine. J Pain Symptom Manage 1992; 7: 204-8. Cade L, Ashley J, Ross AW. Comparison of epidural and intravenous opioid analgesia after elective caesarean section. Anaesth Intensive Care 1992; 20: 41-5. McKenzie R, Rudy T, Ponter-Hammill M. Side-effects of morphine patient-controlled analgesia and meperidine patientcontrolled analgesia: a follow-up of 500 patients. J Assoc Nurse Anesth 1992; 60: 282-6. Woodhouse A, Hobbes AFT, Mather LE, Gibson M. A comparison of morphine, pethidine and fentanyl in the post-surgical patient-controlled analgesia environment. Pain 1996; 64: 115-21. Stanley G, Appadu 8, Mead M, Rowbotham DJ. Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery. Br J Anaesth 1996; 76: 484-6. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180-5. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation. Tucson, AZ: Neuropsychology Press, 1985: 61-4. Dillon WR, Goldstein M. Multivariate analysis. Methods and applications. New York: John Wiley and Sons, 1984: 23-52. Owen H, Plummer JL, Armstrong I, et al. Variables of patientcontrolled analgesia. 1. Bolus size. Anaesthesia 1989; 44: 7-10. Mitsuhata H, Matsumoto S, Hasegawa J. Intravenous patientcontrolled analgesia with pethidine for the treatment of postoperative pain in patients undergoing upper abdominal surgery. Masui 1992; 41: 92-9. Cade L, Ashley J. Towards optimal analgesia after caesarean section: comparison of epidural and intravenous patientcontrolled opioid analgesia. Anaesth Intensive Care 1993; 21: 416-9. Marcantonio ER, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. JAMA 1994; 272: 1518-22. Tune LE, Damlouji NF, Holland A, et al. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 1981; 2: 651-3.

Dietary intake of sodium, and ii ; to ensure that the patient is compliant. If this does not help, it is wise to add a thiazide. Added benefit from coadministration of thiazide and loop diuretics concerns not only increased natriuretic effect, but also diminished calciuresis, since increased calcium loss with loop diuretics is antagonized by thiazides. The therapeutic options in renal patients resistant to loop diuretic treatment are summarized in Table 1 and methadone. METHODS A retrospective review was conducted of 20 eyes in 19 patients treated for clinically significant epithelial ingrowth after LASIK with lifting of the flap, scraping of the ingrowth, and suturing of the flap to the stromal bed. All eyes were diagnosed with clinically significant epithelial ingrowth after LASIK and were treated owing to evidence of progressive epithelial ingrowth, peripheral flap melting, topography changes, refractive changes, and or chronic irritation. The preoperative LASIK examination, LASIK surgical report, postoperative course, epithelial ingrowth treatment report, and postepithelial ingrowth treatment examinations were reviewed. Treatment of epithelial ingrowth was performed by a single surgeon E.E.M. ; . After providing informed consent, patients were given topical 0.5% proparacaine hydrochloride Ophthetic; Allergan Inc, Irvine, Calif ; , 0.1% diclofenac sodium Voltaren; Ciba Vision Ophthalmics, Duluth, Ga ; , and 0.3% ciprofloxacin hydrochloride Ciloxan; Alcon Laboratories Inc, Fort Worth, Tex ; in the operated-on eye immediately before the procedure. Patients were taken to the laser and reclined in a supine position. A sterile drape and a wire lid speculum were placed in the operated-on eye. The flap was lifted using a LASIK spatula. The epithelial ingrowth was scraped from the posterior surface of the flap and from the keratectomy bed using a blunt photorefractive keratectomy spatula AE-2767 Maloney spatula; ASICO, Westmont, Ill ; . After repositioning of the flap, the interface was irrigated with balanced saline solution. The flap was sutured into place with 10-0 nylon, using a total of 5 to interrupted sutures. The eye was then irrigated with balanced salt solution, followed by 0.3% ciprofloxacin. Also administered were 0.1% diclofenac and 1% prednisolone acetate Pred Forte; Allergan Inc ; , and a bandage contact lens was placed. Patients were treated postoperatively with 0.3% ciprofloxacin hydrochloride 4 times a day and 1% prednisolone acetate 4 times a day. Once the epithelium was healed, the bandage contact lens was removed, and 0.1% fluorometholone acetate Flarex; Alcon Laboratories Inc ; was given 2 times a day for 2 weeks. Outcome measures included recurrence of epithelial ingrowth on slitlamp biomicroscopy results, uncorrected visual acuity UCVA ; , manifest refraction, and best spectaclecorrected visual acuity BSCVA ; . Postoperative examinations were performed at 1 day. The frequency of subsequent follow-up examinations varied according to the healing response and was determined by the surgeon. Statistical analysis was performed with the paired t test using Microsoft Excel 2000 Microsoft Corp, Redmond, Wash ; . A P value of .05 was considered statistically significant. For statistical analysis of UCVA and BSCVA, Snellen visual acuity was converted to logarithm of the minimum angle of resolution logMAR ; notation. Unless otherwise indicated, data are expressed as meanSD. Tabolite of atracurium 0.3 mg per liter meperidine 0.7 mg per liter and lidocaine 5.2 mg per liter ; Table 1 and methazolamide and meperidine.

That were nondiagnostic biopsy. A firm nodule composed were cells of numerous infiltrates of blood red. serum with was then interstitial. Over time, meperidine w promethazine may not work as well and methenamine. Cheap meperidine online PATIENT CHARACTERISTICS Between July 2000 and July 2002, 59 chemonaive patients 43 male, 16 female ; with NSCLC were enrolled in phase I and II portions from the five hospitals after approval by the IRB. Twenty-five patients were enrolled in the phase I portion of the study, and 34 patients were enrolled in phase II. Baseline patient characteristics for all patients and patients who received the recommended regimen are summarized in Table 1.

Severance pay will be made to you on the same days you would have received your pay from UPMC had you not been terminated. Thus, if you were paid every two weeks, severance pay will be made to you every two weeks. If you were paid once a month, severance pay will be made to you once a month. However, in limited circumstances, the Plan Administrator may elect, in its sole discretion, to pay severance pay in a lump sum payment before the severance payments ever begin. ED visits since birth at the 2- to 4-month interviews. The discrepancies between parental reporting and the medical records in this study may be attributed to 2 factors-- inaccurate recall and incomplete medical records. Although the medical record is intended to be the complete source of a child's health care services use history, medical records may not have complete information for care provided at all sites. This may be due to children seeking care at other health care facilities or with other physicians, and the documentation of this care not being sent to the child's primary care physician to be included in the medical record.3 Also ED visits may not be included in the medical record owing to separate information systems that exist within the same health care institution. One hypothesis of our study is that maternal recall is greater for hospitalizations than it is for ED use. Our findings show substantial agreement was found for hospitalizations since birth at both the 2- to 4-month and the 30- to 33-month surveys while s calculated for ED visits since birth at the 2- to 4-month survey also showed substantial agreement but not at the 30- to 33-month survey. These results suggest that parents have greater recall of hospitalizations than ED visits, likely because of the increased acuity of a hospitalization as well as the trauma of the child not being at home.21 Based on previous studies, it is reasonable to assume that recall depends on the seriousness of an event, 10 supporting our hypothesis. We were interested in examining if mothers had greater recall of acute health care events when their child was 2 to 4 months old than when their child was 30 to 33 months old. Analyses showed that beyond chance agreement decreased with increasing age of the child. Other studies suggest that recall depends on the recency of an event.10, 14, 19 The more recent the health care event both hospitalizations and ED visits ; , the greater the parental reporting and recall relative to the medical record. Mothers in our sample seem to be likely to remember the more acute and recent health care event when the child was an infant. Other studies on parental recall of hospitalizations similarly suggest that acute health care events in an infant are imprinted in the parent's memory while time may blur the details and events, and they may be confused with other episodes of health care use.1, 19 Older mothers in our study had greater recall of hospitalizations than did younger mothers when their children were infants. This finding is contrary to those of Pless and Pless10 who found that younger mothers rather than older mothers recalled more accurately. In our study, mothers with higher incomes and more children also had greater recall of recent hospitalizations than mothers for whom this was their first child. This finding is also contrary to the findings from Pless and Pless10 who found that mothers with fewer children had better recall of hospitalizations. No differences in recall were seen by maternal characteristics for ED use and hospitalizations reported at the 30- to 33-month survey. We hypothesized that mothers in the study reporting depressive symptoms overreport acute health care use more often than mothers without depressive symptoms. Recent studies have shown that maternal depressive symptoms are significantly associated with chil.